14 results found.

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using bortezomib; mitoxantrone hydrochloride; etoposide; cytarabine; flow cytometry

Case Comprehensive Cancer Center - Recruiting 18 years to 70 years.
- A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML).
bortezomib; mitoxantrone hydrochloride; etoposide; cytarabine; flow cytometry

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblast Clinical Trial using Sirolimus; Idarubicin; Cytarabine

Thomas Jefferson University - Recruiting 18 years or older.
- A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia.
Sirolimus; Idarubicin; Cytarabine

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using clofarabine; total-body irradiation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 2 years or older.
- A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML.
clofarabine; total-body irradiation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis; pharmacological study

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 74 years.
- Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML).
pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using standard follow-up care; medical chart review; quality-of-life assessment

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 75 years.
- Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML.
standard follow-up care; medical chart review; quality-of-life assessment

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 60 years.
- A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA+V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML).
cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using caspofungin acetate; fluconazole; laboratory biomarker analysis

Children's Oncology Group - Recruiting 3 Months to 30 years.
- A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML).
caspofungin acetate; fluconazole; laboratory biomarker analysis

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study.
decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS.
cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML).
daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using lenalidomide; laboratory biomarker analysis

Albert Einstein College of Medicine of Yeshiva University - Recruiting 60 years to 75 years.
- A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML).
lenalidomide; laboratory biomarker analysis

Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Clinical Trial using asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A to 29 years.
- A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD.
asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using chemotherapy

University of Washington - Recruiting 18 years to 59 years.
- Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome.
chemotherapy

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblast Clinical Trial using azacitidine; cytarabine; mitoxantrone hydrochloride; laboratory biomarker analysis

University of Chicago - Recruiting 18 years or older.
- Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML).
azacitidine; cytarabine; mitoxantrone hydrochloride; laboratory biomarker analysis